Claire Sun

Claire Sun is a Senior Partner at IPO Pang Shenjun. Her practice covers foreign direct investment, market entry, Sino-foreign joint ventures, cross-border mergers and acquisitions, corporate transactions, and civil and commercial dispute resolution. Ms. Sun graduated from the University of Hertfordshire School of Law in the United Kingdom with an LLB (Honours) degree and interned at Allen & Overy in London. With a deep understanding of the Anglo-American legal system and Western business culture, she has practised in Shanghai for fifteen years. She assesses market trends, regulatory conditions and client objectives to arrive at comprehensive and workable solutions, and leads complex foreign direct investment matters including China site setup, brand market entry, Sino-foreign joint ventures, mergers and acquisitions, and the design of exit strategies. She also has extensive experience in civil and commercial dispute resolution across contractual and shareholder disputes, where her litigation background gives her a distinct advantage in handling commercial transactions. Her sector experience spans healthcare, biopharmaceuticals, fintech, smart logistics, entertainment and art. In 2018 she was selected in the first cohort chosen by the Shanghai Bar Association for an international legal exchange training programme in Washington, D.C. In 2025 she was selected as an exchange lawyer for the Huangpu District foreign-related lawyer rule-of-law construction international arbitration programme in Singapore. Representative transactions include an equity investment in an Israeli fetal heart monitoring company that exited following IPO; a joint research, development and licensing arrangement with a foreign innovative pharmaceutical company for a new gastric cancer treatment; a research and development licensing and global commercialisation rights transaction for a new drug with a United States company; seed and subsequent series financing for a biomedicine company alongside a leading international medical fund; the Ping An Tsumura acquisition of traditional Chinese medicine planting land and raw materials; a foreign capital merger and acquisition between a Jiangsu chemical enterprise and a well-known French chemical corporation; the ZACD Group (Singapore) acquisition of domestic real estate transaction projects in China; counsel to UBox Technology (Singapore) on a smart logistics ecosystem project; full-process legal services for the introduction of a Broadway musical performance project; legal compliance advice for a private equity investor across multiple projects in China; an exclusive general agency and distribution new-retail project for a collective of high-end European children's brands; and strategic negotiation and documentation supporting the orderly exit of foreign investors from Sino-foreign cooperation and joint venture arrangements. Representative litigation and arbitration includes an innovative drug licensing agreement dispute in which she acted for the client in a major breach of contract action, winning at both first and second instance, securing USD 3 million in liquidated damages and upholding the upfront payment; a Hong Kong company subsidiary control dispute over control rights across several subsidiaries invested in China, won at both first and second instance and resulting in the replacement of senior management, which laid the foundation for the client to take over the whole family business; a Singapore foreign investor equity transfer involving land and site buildings, in which she successfully secured the transfer payment; and a cross-border service contract arbitration for a United States client at CIETAC (Beijing), in which she successfully secured compensation.